Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATPARP: Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
NCT04288687Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in castration-resistant prostate cancer (CRPC), sponsored by Abramson Cancer Center. Primary endpoint: 6-Month Radiographic Progression-Free Survival. Started Oct 2020; status: completed.
02
Drugs
niraparib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04288687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04288687.